Skip to main content
release_alert
Welcome to the new Scholars 3.0! Read about new features and let us know what you think.
cancel
Journal cover image

Trilaciclib prior to gemcitabine plus carboplatin for metastatic triple-negative breast cancer: phase III PRESERVE 2.

Publication ,  Journal Article
Goel, S; Tan, AR; Rugo, HS; Aftimos, P; Andrić, Z; Beelen, A; Zhang, J; Yi, JS; Malik, R; O'Shaughnessy, J
Published in: Future Oncology (London, England)
October 2022

Triple-negative breast cancer (TNBC) is an aggressive malignancy for which cytotoxic chemotherapy remains the backbone of treatment. Trilaciclib is an intravenous cyclin-dependent kinase 4/6 inhibitor that induces transient cell cycle arrest of hematopoietic stem and progenitor cells and immune cells during chemotherapy exposure, protecting them from chemotherapy-induced damage and enhancing immune activity. Administration of trilaciclib prior to gemcitabine plus carboplatin (GCb) significantly improved overall survival (OS) compared with GCb alone in an open-label phase II trial in patients with metastatic TNBC, potentially through protection and direct activation of immune function. The randomized, double-blind, placebo-controlled, phase III PRESERVE 2 trial will evaluate the efficacy and safety of trilaciclib administered prior to GCb in patients with locally advanced unresectable or metastatic TNBC. Clinical Trial Registration: NCT04799249 (ClinicalTrials.gov).

Duke Scholars

Published In

Future Oncology (London, England)

DOI

EISSN

1744-8301

ISSN

1479-6694

Publication Date

October 2022

Volume

18

Issue

33

Start / End Page

3701 / 3711

Related Subject Headings

  • Triple Negative Breast Neoplasms
  • Randomized Controlled Trials as Topic
  • Pyrimidines
  • Oncology & Carcinogenesis
  • Humans
  • Gemcitabine
  • Carboplatin
  • Antineoplastic Combined Chemotherapy Protocols
  • 1112 Oncology and Carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Goel, S., Tan, A. R., Rugo, H. S., Aftimos, P., Andrić, Z., Beelen, A., … O’Shaughnessy, J. (2022). Trilaciclib prior to gemcitabine plus carboplatin for metastatic triple-negative breast cancer: phase III PRESERVE 2. Future Oncology (London, England), 18(33), 3701–3711. https://doi.org/10.2217/fon-2022-0773
Goel, Shom, Antoinette R. Tan, Hope S. Rugo, Philippe Aftimos, Zoran Andrić, Andrew Beelen, Jingshan Zhang, John S. Yi, Rajesh Malik, and Joyce O’Shaughnessy. “Trilaciclib prior to gemcitabine plus carboplatin for metastatic triple-negative breast cancer: phase III PRESERVE 2.Future Oncology (London, England) 18, no. 33 (October 2022): 3701–11. https://doi.org/10.2217/fon-2022-0773.
Goel S, Tan AR, Rugo HS, Aftimos P, Andrić Z, Beelen A, et al. Trilaciclib prior to gemcitabine plus carboplatin for metastatic triple-negative breast cancer: phase III PRESERVE 2. Future Oncology (London, England). 2022 Oct;18(33):3701–11.
Goel, Shom, et al. “Trilaciclib prior to gemcitabine plus carboplatin for metastatic triple-negative breast cancer: phase III PRESERVE 2.Future Oncology (London, England), vol. 18, no. 33, Oct. 2022, pp. 3701–11. Epmc, doi:10.2217/fon-2022-0773.
Goel S, Tan AR, Rugo HS, Aftimos P, Andrić Z, Beelen A, Zhang J, Yi JS, Malik R, O’Shaughnessy J. Trilaciclib prior to gemcitabine plus carboplatin for metastatic triple-negative breast cancer: phase III PRESERVE 2. Future Oncology (London, England). 2022 Oct;18(33):3701–3711.
Journal cover image

Published In

Future Oncology (London, England)

DOI

EISSN

1744-8301

ISSN

1479-6694

Publication Date

October 2022

Volume

18

Issue

33

Start / End Page

3701 / 3711

Related Subject Headings

  • Triple Negative Breast Neoplasms
  • Randomized Controlled Trials as Topic
  • Pyrimidines
  • Oncology & Carcinogenesis
  • Humans
  • Gemcitabine
  • Carboplatin
  • Antineoplastic Combined Chemotherapy Protocols
  • 1112 Oncology and Carcinogenesis